Global latest Pharmaceutical and Healthcare disease pipeline guide Benign Prostatic Hyperplasia Pipeline Review, H2 2017, provides an overview of the Benign Prostatic Hyperplasia Male Health pipeline landscape.

Benign Prostatic Hyperplasia BPH is a noncancerous enlargement of the prostate, a small gland that encircles the urethra in males and produces a fluid that makes up part of semen. Symptoms include decreased strength of the urine stream, dribbling after urination, pain during urination, waking at night to urinate, difficulty starting a urine stream. Treatment options for BPH include surgery and medications.

Download FREE Sample of this Report @ https://www.24marketreports.com/report-sample/benign-prostatic-hyperplasia---pipeline-review-h2-2017-market-100

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Benign Prostatic Hyperplasia Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Benign Prostatic Hyperplasia Male Health, complete with analysis by stage of development, drug target, mechanism of action MoA, route of administration RoA and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Benign Prostatic Hyperplasia Male Health pipeline guide also reviews of key players involved in therapeutic development for Benign Prostatic Hyperplasia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in PreRegistration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 9, 5, 5, 1, 7 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Benign Prostatic Hyperplasia Male Health pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Benign Prostatic Hyperplasia Male Health.
The pipeline guide reviews pipeline therapeutics for Benign Prostatic Hyperplasia Male Health by companies and universities/research institutes based on information derived from company and industryspecific sources.
The pipeline guide covers pipeline products based on several stages of development ranging from preregistration till discovery and undisclosed stages.
The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
The pipeline guide reviews key companies involved in Benign Prostatic Hyperplasia Male Health therapeutics and enlists all their major and minor projects.
The pipeline guide evaluates Benign Prostatic Hyperplasia Male Health therapeutics based on mechanism of action MoA, drug target, route of administration RoA and molecule type.
The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
The pipeline guide reviews latest news related to pipeline therapeutics for Benign Prostatic Hyperplasia Male Health
Get the Complete Report & TOC @ https://www.24marketreports.com/life-sciences/benign-prostatic-hyperplasia---pipeline-review-h2-2017-market-100

Table of content

Introduction 8
Global Markets Direct Report Coverage 8
Benign Prostatic Hyperplasia Overview 9
Benign Prostatic Hyperplasia Therapeutics Development 10
Pipeline Overview 10
Pipeline by Companies 11
Pipeline by Universities/Institutes 14
Products under Development by Companies 15
Products under Development by Universities/Institutes 17
Benign Prostatic Hyperplasia Therapeutics Assessment 18
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Benign Prostatic Hyperplasia Companies Involved in Therapeutics Development 26
Addex Therapeutics Ltd 26
AndroScience Corp 26
Aphios Corp 26
Astellas Pharma Inc 27
BCWorld Pharm Co Ltd 27
Biolab Farmaceutica Ltda 28
Chong Kun Dang Pharmaceutical Corp 28


If You Have Any Question Related To This Report Contact Us @ https://www.24marketreports.com/enquire-now/benign-prostatic-hyperplasia---pipeline-review-h2-2017-market-100

CONTACT US:
276 5th Avenue, New York , NY 10001,United States
International: (+1) 646 781 7170
Fax: (+1) 212 634 4885
Email: [email protected]

Follow Us On linkedin :- https://www.linkedin.com/company/24-market-reports